Beijing Percans Oncology

Percans Oncology is a clinical-stage biotechnology company headquartered in Beijing, specializing in the discovery and development of precision oncology therapeutics. The company utilizes a proprietary drug discovery platform that integrates cancer stem cell biology and DNA damage response mechanisms to target refractory and resistant cancers. Its lead program, PC-002, is a first-in-class small molecule currently in Phase 1/2 clinical trials for various solid tumors and hematological malignancies. Percans aims to address significant unmet medical needs by focusing on the selective elimination of cancer cells while sparing healthy tissue. The firm is backed by prominent venture capital investors including IDG Capital and Northern Light Venture Capital.